57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension

Key Takeaways Explain This Topic AI

Metabolic dysfunction-associated steatotic liver disease (MASLD) requires hepatic steatosis on imaging or biopsy plus at least one cardiometabolic risk factor (overweight/obesity, type 2 diabetes/prediabetes, hypertension, hypertriglyceridemia, or low HDL) without excessive alcohol consumption.

Primary care fibrosis risk stratification utilizes the Fibrosis-4 (FIB-4) index: scores <1.30 (<2.0 in age >=65) possess >90% negative predictive value for advanced fibrosis, whereas scores 1.30-2.67 mandate secondary testing with transient elastography (FibroScan), and scores >2.67 require hepatology referral.

Resmetirom is an oral, liver-directed thyroid hormone receptor-beta (THR-beta) agonist FDA-approved for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3); GLP-1 receptor agonists (semaglutide) and pioglitazone provide substantial metabolic and histologic benefit.

Ascites from portal hypertension is confirmed by a Serum-Ascites Albumin Gradient (SAAG) >=1.1 g/dL; first-line therapy combines dietary sodium restriction (2,000 mg daily) with spironolactone and furosemide in a 100 mg : 40 mg ratio, while large-volume paracentesis (>5 L) requires 6 to 8 g IV albumin per liter removed.

Spontaneous bacterial peritonitis is defined by an ascitic fluid PMN count >=250 cells/mm3 and requires empiric IV ceftriaxone plus IV albumin (1.5 g/kg at diagnosis, 1.0 g/kg on day 3) to prevent hepatorenal syndrome; all cirrhotic patients require biannual abdominal ultrasound +/- AFP for hepatocellular carcinoma surveillance.

Last updated: September 2026

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD & MASH)

Chronic liver disease is a leading cause of premature morbidity and mortality in primary care. Driven by the global syndemic of obesity and type 2 diabetes, steatotic liver disease has emerged as the most prevalent chronic liver disease worldwide, affecting approximately 30% of adults.

Multi-Society Nomenclature Update

In 2023, an international consensus panel representing AASLD, EASL, and ALEH updated the nomenclature from non-alcoholic fatty liver disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) , and from non-alcoholic steatohepatitis (NASH) to Metabolic Dysfunction-Associated Steatohepatitis (MASH) . This affirmative diagnostic framework removes exclusionary and stigmatizing terminology, anchoring the disease directly to underlying cardiometabolic pathophysiology:

MASLD Definition : Presence of hepatic steatosis (demonstrated by imaging, blood biomarkers, or histology) in the presence of at least one of five cardiometabolic risk factors , in the absence of other secondary causes of hepatic fat accumulation and without excessive alcohol intake:

Overweight / Obesity : BMI >=25 kg/m² (>=23 kg/m² in Asian individuals) OR waist circumference >94 cm (men) / >80 cm (women).

Dysglycemia : Fasting plasma glucose >=100 mg/dL (5.6 mmol/L), 2-hour post-oral glucose load >=140 mg/dL, HbA1c >=5.7%, or diagnosed Type 2 diabetes mellitus or specific antidiabetic pharmacotherapy.

Hypertension : Blood pressure >=130/85 mmHg or documented antihypertensive medication use.

Hypertriglyceridemia : Plasma triglycerides >=150 mg/dL (1.70 mmol/L) or lipid-lowering treatment.

Low HDL Cholesterol : Plasma HDL-C <40 mg/dL (1.0 mmol/L) in men, <50 mg/dL (1.3 mmol/L) in women, or specific drug therapy.

Alcohol Consumption Thresholds :

MASLD strictly requires alcohol consumption to be <20 g/day for women (<1.5 standard US drinks daily) and <30 g/day for men (<2 standard drinks daily).

Patients with hepatic steatosis who meet cardiometabolic criteria but consume higher amounts of alcohol (20 to 50 g/day for women, 30 to 60 g/day for men) are classified as having MetALD (Metabolic and Alcohol-Related Liver Disease) , recognizing the synergistic hepatotoxic effect of metabolic dysfunction and alcohol.

Histopathologic Spectrum: Steatosis vs. Steatohepatitis (MASH)

Simple Steatosis (MASL) : Triglyceride accumulation within the cytoplasm of >5% of hepatocytes without significant hepatocellular injury or inflammation. Carries a low rate of fibrotic progression.

MASH (Steatohepatitis) : Steatosis accompanied by lobular inflammation and hepatocyte ballooning degeneration (cytoskeletal swelling and disruption by Mallory-Denk bodies). Hepatocyte lipotoxicity activates immune cascades and hepatic stellate cells, driving progressive perisinusoidal, "chicken-wire" fibrosis that advances from Stage F0 (no fibrosis) to F1 (perisinusoidal), F2 (perisinusoidal and periportal), F3 (bridging fibrosis), and F4 (frank cirrhosis).

Non-Invasive Fibrosis Risk Assessment: The FIB-4 Index & Elastography Algorithms

In MASLD, long-term liver-related morbidity, cardiovascular events, and all-cause mortality are dictated almost exclusively by the stage of hepatic fibrosis , rather than the absolute quantity of liver fat. Because liver biopsy carries procedural risks and sampling error, multi-society clinical practice guidelines mandate non-invasive fibrosis risk stratification for all patients with MASLD in primary care.

First-Line Screening: The Fibrosis-4 (FIB-4) Index

The FIB-4 Index is calculated using four universally accessible clinical parameters: FIB-4 = Age (years) × AST (U/L) Platelet Count ( 10 9 / L ) × ALT (U/L) \text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet Count } (10^9/\text{L}) \times \sqrt{\text{ALT (U/L)}}} FIB-4 = Platelet Count ( 1 0 9 / L ) × ALT (U/L) ​ Age (years) × AST (U/L) ​ PRIMARY CARE FIB-4 RISK STRATIFICATION

• FIB-4 Score Range Fibrosis Risk Tier Clinical Interpretation & Actionable Pathway
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• < 1.30 LOW RISK High Negative Predictive Value (>90-95%) for

(< 2.0 in age >=65) advanced fibrosis (F3-F4). Excludes advanced disease.

• Manage in primary care with lifestyle counseling
• Optimize diabetes, hypertension, and lipids
• Repeat FIB-4 every 2 to 3 years

1.30 to 2.67 INTERMEDIATE / Indeterminate score; advanced fibrosis cannot be

INDETERMINATE RISK excluded.

• Reflex to secondary non-invasive testing:

• Vibration-Controlled Transient Elastography (VCTE)
• OR Enhanced Liver Fibrosis (ELF) serum test

> 2.67 HIGH RISK High Positive Predictive Value for advanced fibrosis

(F3) or cirrhosis (F4).

• Expedited referral to Gastroenterology / Hepatology
• Screen for portal hypertension and cirrhosis
• Initiate biannual HCC surveillance if cirrhotic
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• *Age Adjustment: In patients aged >=65 years, physiological shifts alter transaminases; the lower cutoff

is adjusted upward to <2.0 to prevent excessive false-positive results.

Secondary Non-Invasive Testing: Transient Elastography (VCTE / FibroScan)

Patients in the intermediate-risk tier (or high-risk tier for staging confirmation) undergo secondary non-invasive evaluation with Vibration-Controlled Transient Elastography (VCTE / FibroScan) , which measures shear-wave velocity to quantify liver stiffness in kilopascals (kPa):

Liver Stiffness < 8.0 kPa : Low risk of advanced fibrosis (F0-F1). Patient can remain in primary care for ongoing metabolic optimization and repeat elastography in 3 years.

Liver Stiffness 8.0 to 12.0 kPa : Moderate/advanced fibrosis (F2-F3). Referral to hepatology for disease-modifying therapy and clinical trial consideration.

Liver Stiffness >= 12.0 to 15.0 kPa : Advanced fibrosis to cirrhosis (F3-F4). High risk of portal hypertension; mandates hepatology co-management, variceal screening, and HCC surveillance.

Enhanced Liver Fibrosis (ELF) Score : A proprietary serum test measuring hyaluronic acid, procollagen III N-terminal peptide, and tissue inhibitor of metalloproteinase 1. An ELF score <7.7 indicates low risk, 7.7 to 9.8 intermediate risk, and >=9.8 indicates advanced fibrosis.

Evidence-Based Pharmacotherapy & Management for MASLD/MASH

Lifestyle Interventions & Weight Loss Targets :

A direct, dose-dependent relationship exists between the magnitude of weight loss and histologic liver improvement:

>=3% to 5% weight loss : Achieves significant reduction in hepatic steatosis.

>=7% to 10% weight loss : Induces resolution of steatohepatitis (MASH) and halts or reverses hepatic fibrosis in up to 50% to 80% of patients.

Dietary Pattern : The Mediterranean diet —rich in monounsaturated fatty acids, omega-3 fatty acids, fresh vegetables, legumes, and extra-virgin olive oil, while severely restricting ultra-processed foods, saturated fats, and high-fructose corn syrup beverages—is the gold standard.

Exercise : At least 150 minutes per week of moderate-intensity aerobic exercise paired with resistance training.

Resmetirom (Rezdiffra) :

The first FDA-approved medication for non-cirrhotic MASH with moderate-to-advanced liver fibrosis (stages F2-F3), used as an adjunct to diet and exercise.

Mechanism of Action : A liver-directed, oral thyroid hormone receptor-beta (THR-beta) agonist . THR-beta is the predominant thyroid hormone receptor subtype in hepatocytes. By selectively stimulating hepatic THR-beta without activating cardiac or bone THR-alpha receptors, resmetirom increases hepatic mitochondrial fatty acid beta-oxidation, decreases toxic lipotoxic intermediates, promotes MASH resolution, and reverses fibrosis.

Dosing : Weight-based: 80 mg PO once daily for body weight <100 kg, and 100 mg PO once daily for body weight >=100 kg.

Safety Pearls : Most common adverse effects are transient diarrhea and nausea; monitor for drug-drug interactions with statins (increases statin exposure; cap rosuvastatin at 20 mg daily).

Incretin Mimetics (GLP-1 Receptor Agonists & Dual Incretins) :

Semaglutide (and tirzepatide) produces robust, sustained weight reduction (10% to 20%), drives resolution of steatohepatitis, and reduces major adverse cardiovascular events (MACE). Although FDA approvals have primarily focused on diabetes and obesity, current guidelines strongly endorse GLP-1 RAs as preferred cardiometabolic therapy in patients with MASLD/MASH.

Pioglitazone :

A peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist (30 to 45 mg daily) that enhances peripheral and hepatic insulin sensitivity. Proven in biopsy-controlled trials to improve steatosis and lobular inflammation in patients with type 2 diabetes or prediabetes. Adverse effects include weight gain, fluid retention/peripheral edema, heart failure precipitation, and decreased bone density.

Vitamin E (Alpha-Tocopherol) :

An antioxidant (800 IU daily) that improves liver histology in non-diabetic adults with biopsy-proven MASH (PIVENS trial). Not recommended for diabetic patients or without biopsy confirmation; long-term use warrants caution regarding potential modest increases in all-cause mortality, prostate cancer, and hemorrhagic stroke.

Cirrhosis & Portal Hypertension: Staging, Scoring & Pathophysiology

Cirrhosis is the histopathological end stage of chronic liver disease, defined by diffuse architectural disruption, regenerative parenchymal nodules, and dense bands of bridging fibrous septa.

Pathophysiology of Portal Hypertension

Portal hypertension is defined as a hepatic venous pressure gradient (HVPG) >5 mmHg; clinical complications emerge when the HVPG reaches >=10 mmHg (clinically significant portal hypertension, CSPH) :

Increased Intrahepatic Vascular Resistance : Structural distortion from dense extracellular collagen deposition and vascular remodeling. In addition, activated hepatic stellate cells and sinusoidal endothelial cells demonstrate functional deficiency of endogenous vasodilator nitric oxide (NO) and hyperresponsiveness to vasoconstrictors (endothelin-1), increasing sinusoidal tone.

Hyperdynamic Splanchnic Circulation : Severe shear stress and localized inflammation trigger massive release of splanchnic vasodilators (predominantly nitric oxide). This results in profound arteriolar vasodilation throughout the mesenteric and splanchnic arterial beds.

Splanchnic Inflow & Arterial Underfilling : Massive splanchnic arterial inflow floods into the portal vein against elevated intrahepatic resistance, creating high portal pressures. Systemically, splanchnic pooling causes effective arterial hypovolemia, triggering reflex compensatory hyperactivation of the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and non-osmotic release of antidiuretic hormone (ADH), driving renal sodium and water retention.

Prognostic Staging Systems: Child-Pugh & MELD-Na THE CHILD-PUGH CLASSIFICATION SYSTEM

• Clinical / Laboratory Variable 1 Point 2 Points 3 Points
• ═════════════════════════════════════════════════════════════════════════════
• Serum Total Bilirubin (mg/dL) < 2.0 2.0 to 3.0 > 3.0
• Serum Albumin (g/dL) > 3.5 2.8 to 3.5 < 2.8
• Prothrombin Time INR < 1.7 1.7 to 2.2 > 2.2
• Ascites Severity None Mild / Med Moderate to Severe
• controlled (refractory)
• Hepatic Encephalopathy None Grade 1-2 Grade 3-4
• (mild/asterixis) (severe/coma)
• ═════════════════════════════════════════════════════════════════════════════
• Child-Pugh Class A: 5 to 6 points | Well-compensated disease; 1-yr survival ~100%
• Child-Pugh Class B: 7 to 9 points | Significant functional compromise; 1-yr survival ~80%
• Child-Pugh Class C: 10 to 15 points | Decompensated end-stage disease; 1-yr survival ~45%

Model for End-Stage Liver Disease - Sodium (MELD-Na) :

An objective mathematical model incorporating four laboratory parameters: Serum Total Bilirubin, INR, Serum Creatinine, and Serum Sodium (with adjustments for patients receiving hemodialysis).

Scores range from 6 to 40 , accurately calculating objective 90-day mortality risk in patients with end-stage liver disease. MELD-Na serves as the universal legal metric for deceased-donor liver organ allocation via UNOS/OPTN throughout the United States. Patients with MELD-Na >=15 should be formally evaluated for liver transplantation.

Evidence-Based Management of Cirrhotic Complications

Decompensation transforms compensated cirrhosis into a multi-system, life-threatening disorder. The development of variceal hemorrhage, ascites, spontaneous bacterial peritonitis, or hepatic encephalopathy marks a dramatic decrease in median survival. EVIDENCE-BASED MANAGEMENT OF CIRRHOTIC COMPLICATIONS

• Complication Diagnostic Criteria First-Line Therapeutic Management
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Gastroesophageal Screening EGD at cirrhosis Primary Prophylaxis: Non-selective beta-blocker
• Varices diagnosis (or defer if VCTE (Carvedilol 6.25-12.5 mg daily preferred; or
• <20 kPa and platelets >150k) Nadolol/Propranolol) OR Endoscopic Variceal
• Ligation (EVL / banding)

• Ascites Ultrasound / paracentesis; • Sodium restriction: 2,000 mg/day (88 mmol/d)
• SAAG >= 1.1 g/dL indicates • Dual diuretics: Spironolactone + Furosemide
• portal hypertension (100 mg : 40 mg ratio; max 400 mg : 160 mg)
• Large-volume paracentesis (>5 L): 6-8 g
• IV albumin per liter removed

• Spontaneous Ascitic fluid absolute PMN • IV Ceftriaxone 2 g daily for 5 days
• Bacterial count >= 250 cells/mm³ • IV Albumin: 1.5 g/kg within 6 hours,
• Peritonitis (SBP) (neutrophils) followed by 1.0 g/kg on Day 3
• Secondary prophylaxis: lifelong daily oral
• TMP-SMX DS (1 tab daily) or Ciprofloxacin

• Hepatic West Haven criteria; • Lactulose titrated to 2 to 3 soft stools/day
• Encephalopathy (HE) asterixis, cognitive change; • Add Rifaximin 550 mg PO twice daily for recurrence
• identify precipitants • DO NOT restrict dietary protein (1.2-1.5 g/kg/d)

• Hepatocellular All cirrhotic patients Abdominal Ultrasound with or without serum
• Carcinoma (HCC) regardless of etiology Alpha-Fetoprotein (AFP) every 6 months
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• 1. Gastroesophageal Varices & Primary Prophylaxis

Screening : All patients with newly diagnosed cirrhosis should undergo screening EGD. Under Baveno VII criteria, screening EGD may be safely deferred if liver stiffness on transient elastography is <20 kPa AND platelet count is >150,000/mcL.

Indications for Primary Prophylaxis : Medium-to-large varices (>=5 mm), small varices with red wale markings, or Child-Pugh Class C cirrhosis with any varices.

Non-Selective Beta-Blockers (NSBB) :

Carvedilol (6.25 mg daily titrated to 12.5 mg daily) is the preferred NSBB : provides combined β 1 / β 2 \beta_1/\beta_2 β 1 ​ / β 2 ​ blockade plus intrinsic α 1 \alpha_1 α 1 ​ -adrenergic antagonism, which dilates intrahepatic sinusoids while constricting splanchnic arteries, achieving greater portal pressure reduction than traditional agents.

Traditional NSBBs: Nadolol (20 to 40 mg daily) or Propranolol (20 to 40 mg BID), titrated to achieve a resting heart rate of 55 to 60 bpm with systolic blood pressure maintained >=90 mmHg. Mechanism: β 1 \beta_1 β 1 ​ blockade reduces cardiac output, while β 2 \beta_2 β 2 ​ blockade produces unopposed splanchnic α 1 \alpha_1 α 1 ​ vasoconstriction, reducing portal inflow.

Endoscopic Variceal Ligation (EVL) : Recommended for patients with contraindications, intolerance, or hypotension preventing NSBB therapy.

2. Ascites & Large-Volume Paracentesis

Diagnostic Paracentesis : Mandatory in all patients presenting with new-onset ascites, hospital admission with cirrhosis, or acute clinical deterioration.

Serum-Ascites Albumin Gradient (SAAG) : Calculated as: SAAG = Serum Albumin − Ascitic Fluid Albumin \text{SAAG} = \text{Serum Albumin} - \text{Ascitic Fluid Albumin} SAAG = Serum Albumin − Ascitic Fluid Albumin .

SAAG >= 1.1 g/dL (High Gradient) : Indicates portal hypertension with 97% accuracy. Causes include cirrhosis (ascitic total protein <2.5 g/dL), congestive heart failure / constrictive pericarditis (ascitic total protein >=2.5 g/dL), and Budd-Chiari syndrome.

SAAG < 1.1 g/dL (Low Gradient) : Indicates non-portal causes (no capillary hydrostatic hypertension). Causes include peritoneal carcinomatosis, tuberculous peritonitis, nephrotic syndrome, and pancreatic ascites.

Medical Management :

Dietary Sodium Restriction : Strictly limited to 2,000 mg/day (88 mmol/day) . Extreme fluid restriction (<1.5 L/day) is NOT indicated unless profound hypervolemic hyponatremia (serum Na <120 to 125 mEq/L) is present.

Dual Diuretic Therapy : Spironolactone (aldosterone antagonist) + Furosemide (loop diuretic) administered in a fixed single morning ratio of 100 mg : 40 mg . This specific ratio maintains normokalemia and targets a urinary Na/K ratio >1. Dosages can be titrated stepwise every 3 to 5 days up to a maximum of 400 mg spironolactone and 160 mg furosemide daily.

Large-Volume Paracentesis (LVP > 5 Liters) :

When removing >5 liters of ascitic fluid, administration of intravenous albumin (20% or 25% formulation) at a dose of 6 to 8 grams per liter of ascites removed is mandatory.

Clinical Rationale : Prevents Paracentesis-Induced Circulatory Dysfunction (PICD) —a catastrophic syndrome characterized by severe peripheral vasodilation, rapid decline in effective circulating arterial volume, activation of the RAAS, acute kidney injury (hepatorenal syndrome), and early mortality.

3. Spontaneous Bacterial Peritonitis (SBP)

Pathogenesis : Translocation of enteric Gram-negative bacilli ( Escherichia coli , Klebsiella pneumoniae ) or streptococci across a permeable intestinal wall into ascitic fluid lacking adequate opsonic activity.

Diagnostic Threshold : Ascitic fluid Absolute Neutrophil Count (ANC / PMN count) >= 250 cells/mm³ (calculated as total fluid WBC × \times × % neutrophils). Treatment must begin immediately based on PMN count without waiting for culture results.

Antimicrobial Therapy : Empiric IV third-generation cephalosporin ( Ceftriaxone 2 g IV every 24 hours or Cefotaxime 2 g IV q8h) for 5 days .

Mandatory IV Albumin Infusion : Administer IV albumin at 1.5 g/kg within 6 hours of diagnosis, followed by 1.0 g/kg on Day 3 . Landmark trials demonstrate this protocol reduces the incidence of hepatorenal syndrome from 33% to 10% and cuts in-hospital mortality from 29% to 10%.

Lifelong Secondary Prophylaxis : All patients recovering from an episode of SBP mandate indefinite oral prophylaxis with Trimethoprim-Sulfamethoxazole (one DS tablet daily) or Ciprofloxacin (500 mg daily) .

4. Hepatic Encephalopathy (HE)

Pathogenesis : Portosystemic shunting and impaired hepatic urea synthesis allow neurotoxins, predominantly ammonia ( N H 3 NH_3 N H 3 ​ ) , to cross the blood-brain barrier. Astrocytes metabolize ammonia to glutamine, producing cerebral edema, neurosteroid dysregulation, and GABAergic neuroinhibition.

Clinical Manifestations : Inversion of sleep-wake cycle, cognitive slowing, irritability, lethargy, marked confusion, and asterixis (bilateral, asynchronous flapping tremor elicited on wrist dorsiflexion with arms extended) .

Identifying Triggers : Encephalopathy is almost invariably precipitated by an acute intercurrent event. Always identify and treat the underlying trigger: Infection (SBP, UTI, pneumonia), Gastrointestinal bleeding (digested blood acts as a massive protein load), Constipation, Hypokalemia and metabolic alkalosis (promotes conversion of uncharged N H 3 NH_3 N H 3 ​ that crosses the blood-brain barrier), Dehydration, or Sedating medications .

Medical Therapy :

Lactulose : First-line. A non-absorbable disaccharide. Colonic bacteria ferment lactulose into lactic and acetic acid, acidifying the colonic lumen (pH <5.0). Acidification protonates ammonia ( N H 3 NH_3 N H 3 ​ ) into unabsorbable ammonium ( N H 4 + NH_4^+ N H 4 + ​ ), trapping it in the stool ("ammonia trapping"), while exerting an osmotic laxative effect. Titrate to achieve 2 to 3 soft bowel movements per day .

Rifaximin (550 mg PO twice daily) : A minimally absorbed oral rifamycin antibiotic that suppresses gut urease-producing bacteria, decreasing intestinal ammonia generation. Adding rifaximin to lactulose significantly reduces recurrent encephalopathy hospitalizations and mortality.

Dietary Counseling : Strict dietary protein restriction is harmful and contraindicated ! Cirrhotic patients are in a state of accelerated starvation; skeletal muscle is the primary alternative site for ammonia detoxification. Patients must maintain a high-protein diet ( 1.2 to 1.5 g/kg/day ) to preserve muscle mass and prevent sarcopenia.

5. Hepatocellular Carcinoma (HCC) Surveillance

Cirrhosis of any etiology is the single greatest risk factor for hepatocellular carcinoma. Current AASLD and EASL practice guidelines mandate surveillance with abdominal ultrasound with or without serum Alpha-Fetoprotein (AFP) every 6 months for all patients with cirrhosis (Child-Pugh A, B, or C awaiting transplant). Any newly detected solid liver nodule >=1.0 cm requires dynamic multi-phase contrast-enhanced CT or MRI applying Liver Imaging Reporting and Data System ( LI-RADS ) diagnostic criteria.

Loading diagram... Clinical Algorithm for MASLD Risk Stratification, Cirrhosis Prognosis & Complication Management